US Patent 10544418 RNAi inhibition of alpha-ENaC expression
Patent 10544418 was granted and assigned to Arrowhead Pharmaceuticals, Inc. on January, 2020 by the United States Patent and Trademark Office.
All edits
Edits on 17 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 11 Dec, 2023
Golden AI
Edits made to:
Article (+219 characters)
Article
Patent abstract
The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
Edits on 4 Oct, 2023
Golden AI
Edits made to:
Infobox (+6 properties)
Infobox
Patent Inventor Names
Anke Geick0
Emma Hickman0
Gino Van Heeke0
Hans-Peter Vornlocher0
Henry Luke Danahay0
Pamela Tan0
Edits on 1 Feb, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10544418 RNAi inhibition of alpha-ENaC expression
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10544418
Date of patent
January 28, 2020
Patent application number
15874396
Date Filed
January 18, 2018
Patent primary examiner
Find more entities like US Patent 10544418 RNAi inhibition of alpha-ENaC expression
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.